Cidara Therapeutics announces two presentations on CD388

Cidara Therapeutics announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic data from clinical studies of CD388, Cidara’s influenza drug-Fc conjugate candidate. “We are pleased to have the opportunity to present at this year’s OPTIONS XII conference and share the clinical data on our universally active influenza preventative, CD388,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “These data support the safety of CD388 administered over a range of doses via multiple routes of administration. Moreover, the pharmacokinetic data support the potential use of CD388 in immune compromised as well as immune competent populations to provide season-long protection against influenza A and B.”